Eledon Pharmaceuticals, Inc. (ELDN) Earnings Call Transcripts

Eledon Pharmaceuticals, Inc.'s Latest Earnings Call - June 22, 2026

In the second quarter of fiscal year 2026, Eledon Pharmaceuticals reported significant advancements in its clinical programs, particularly for its lead asset, tegoprubart. The company presented compelling long-term data at the American Transplant Congress, highlighting superior kidney function outcomes and safety profiles compared to tacrolimus. Management maintained guidance for the upcoming Phase III study, which is expected to start by the end of this year, indicating strong momentum in their transplant programs. Revenue and earnings figures were not disclosed during the call, but the positive clinical data could enhance investor sentiment and drive stock performance going forward.

Reported metrics

Guidance from management

Management confirmed that the Phase III study for kidney transplantation is on track to begin by the end of 2026, maintaining their previous guidance and focusing on key efficacy endpoints related to kidney function and safety.

What management said

Sure. So preliminary guidance from the FDA aligns with precedent in regards to the approvals that have been granted to date, one in particular, that DA mentioned, the Lantidra approval, but also publicly available information regarding programs that have been given a go ahead for, to proceed towards a BLA. So the numbers that are shown in our slides align exactly with that prescedent and publicly available guidance f...

And here, it's D.A again, at ATC, we're presenting the data both in the poster as well as an oral session and at poster physician after physician commented on the fact that we were not seeing acute rejection after 6 months. So people definitely found it striking.

What analysts pressed on

Analysts expressed concerns regarding the FDA's pending feedback on the ibox measure and its potential implications for the study. Additionally, there were questions about the long-term safety and efficacy of switching patients from tacrolimus to tegoprubart after initial treatment.

Main topics on the call

• Clinical Data Presentation — Eledon presented long-term kidney transplant data showing 'higher kidney function, reaching statistical superiority at 18 months' with tegoprubart compared to tacrolimus, which continues to show ongoing rejections. The d...
• Phase III Study Plans — Management confirmed plans to initiate a Phase III study by the end of 2026, which will enroll approximately 600 patients. The primary endpoint will focus on a composite measure of biopsy-proven acute rejection, graft lo...
• Patient-Reported Outcomes — For the first time, patient-reported outcomes were presented, showing 'statistical and clinically meaningful differences' favoring tegoprubart over tacrolimus in symptom burden and quality of life metrics. This highlight...
• Safety Profile Comparison — The safety profile of tegoprubart continues to show advantages over tacrolimus, with management noting 'more acute kidney injury about 3x more in the Tac arm' and 'no cases of BPAR in the Tego arm after 6 months.' This s...

Read the full Eledon Pharmaceuticals, Inc. transcript (June 22, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 20 Eledon Pharmaceuticals, Inc. earnings call transcripts on record, spanning September 15, 2020 to June 22, 2026. Based on this history, Eledon Pharmaceuticals, Inc. reports quarterly. The most recent call on file is dated June 22, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

ELDN

Exchange

NasdaqCM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

20

First call

September 15, 2020

Most recent

June 22, 2026

Reporting cadence

quarterly